Keywords: Cyclin-dependent kinase 4/6 inhibitor; Drug-induced vasculitis; Faslodex; Fulvestrant; Ibrance; Vasculitis treatment;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Metastatic breast cancer; Efficacy; Endocrine treatment; Fulvestrant; Obesity; BMI;
Keywords: Erlotinib; Fulvestrant; Lung cancer; EGFR; Estrogen; Estrogen receptor;
Keywords: Male breast cancer; Estrogen and progesterone receptors; Ki-67; HER2; Aromatase inhibitors; Tamoxifen; Fulvestrant;
Keywords: TSC; tobacco smoke condensate; ER; estrogen receptor; EDR cells; estrogen depletion-resistant cells; E2; estradiol; ERE; estrogen-responsive element; GFP; green fluorescent protein; AI; aromatase inhibitors; Tam; 4-hydroxytamoxifen; Ful; fulvestrant; B[a]
Keywords: BC; Breast cancer; CRM-1; Chromosome region maintenance 1; DBD; DNA-binding domain; E2; 17-beta-estradiol; EGF; Epidermal growth factor; ERα; Estrogen receptor alpha; Ful; Fulvestrant; GFP-ER; ER tagged with green fluorescent protein; HSP70; Heat shock p
Keywords: Endocrine resistance; Breast cancer; Fulvestrant; Palbociclib; Everolimus; Mechanism of resistance;
Keywords: Circulating tumor cells (CTC); Breast cancer; Hormone receptor positive; Fulvestrant; Aromatase inhibitors; AI; aromatase inhibitor; BCL2; B-cell lymphoma 2; CCS; charcoal stripped calf serum; CTC; circulating tumor cells; EpCAM; epithelial cell adhesion
Keywords: Ovarian cancer; Fulvestrant; Endocrine therapy; Biological therapy; Estrogen receptor; Vimentin;
First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study
Keywords: Advanced breast cancer; First-line; Fulvestrant; Second-line; Overall survival;
Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis
Keywords: Autophagy; Breast cancer; Dual treatment; Fulvestrant; miR-375;
Downregulation of TXNIP leads to high proliferative activity and estrogen-dependent cell growth in breast cancer
Keywords: Estrogen receptor; Fulvestrant; GLUT1; p27; VDUP1;
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Keywords: Buparlisib; Fulvestrant; Hormone receptor-positive breast cancer; Overall survival; PIK3CA; ctDNA;
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
Keywords: Metastatic breast cancer; Premenopausal; Fulvestrant; Endocrine therapy;
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Keywords: Advanced breast cancer; Metastatic; Chemotherapy; Antihormone therapy; Aromatase inhibitor; Fulvestrant; Tamoxifen; Everolimus; Therapy/treatment sequence;
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer
Keywords: Anastrozole; FALCON; Fulvestrant; Health-related quality of life; Locally advanced or metastatic breast cancer;
Estrogenic effects following larval exposure to the putative anti-estrogen, fulvestrant, in the fathead minnow (Pimephales promelas)
Keywords: Fulvestrant; Estrogenic effects; Gene expression; Endocrine disruption; Larval exposure;
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3
Keywords: Palbociclib; Fulvestrant; Advanced breast cancer; HR+/HER2-; Long-term response;
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Keywords: Advanced breast cancer; Age; HR-positive; Endocrine treatment; HER2-negative; Tumour; Letrozole; Fulvestrant; Palbociclib;
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2â) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
Keywords: Everolimus; Hormone-receptor positive; Advanced breast cancer; Fulvestrant; Dose-intensity;
17β-Estradiol modulates cell proliferation of medullary cords during ovarian differentiation of the Lepidochelys olivacea sea turtle
Keywords: Estradiol; Gonad development; Temperature sex determination; Turtle; Fadrozole; Fulvestrant;
ESR1 and its antagonist fulvestrant in pituitary adenomas
Keywords: Pituitary adenomas; Estrogen receptor alpha; Fulvestrant; Apoptosis; MAPK pathway;
Fulvestrant-loaded polymer-based nanoparticles for local drug delivery: Preparation and in vitro characterization
Keywords: Fulvestrant; Breast cancer; Polymer-based nanoparticles; PEG-b-PLGA; PEG-b-PCL; MCF-7;
Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer
Keywords: Breast cancer; Fulvestrant; Estrogen receptor α; DNA methylation; Endocrine therapy resistance; AI; aromatase inhibitor; AE; anti-estrogen; ERα; estrogen receptor α; ERE; estrogen-response element; E2; estradiol; GFP; green fluorescent protein; LBD; li
Clinical predictors of benefit from fulvestrant in advanced breast cancer: A Meta-analysis of randomized controlled trials
Keywords: Fulvestrant; Faslodex; Meta-analysis; Estrogen receptor; Hormonal therapy;
Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
Keywords: Breast cancer; Neoadjuvant treatment; Tamoxifen; Aromatase inhibitors; Fulvestrant; Oestrogen receptor positive
Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer
Keywords: Anterior gradient 2; Fulvestrant; Insulin-like growth factor-1; Estrogen receptor-α; Adjuvant chemotherapy
Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER
Keywords: ER; estrogen receptor; GPER; G protein-coupled estrogen receptor; GPR30; G protein-coupled receptor 30; SERD; selective estrogen receptor downregulator; SERM; selective estrogen receptor modulator; DDT; dichlorodiphenyltrichloroethane; Autoimmune disease;
Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis
Keywords: Afimoxifene; Endoxifen; Raloxifene; Fulvestrant; Sulfation; Cytosolic sulfotransferase; SULTATP, adenosine 5′-triphosphate; CAPS, 3-(cyclohexylamino)-1-propanesulfonic acid; DTT, dithiothreitol; FBS, fetal bovine serum; HEPES, N-2-hydroxylpiperazine-N′-2-
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
Keywords: Advanced breast cancer; Fulvestrant; Selumetinib; Endocrine therapy; MEK 1/2 inhibitor; MAPK pathway;
The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor
Keywords: Breast cancer; Degradation; Endocrine therapy; Estrogen receptor; Fulvestrant; Nuclear localization sequenceAF-1, activation function 1; AF-2, activation function 2; ChIP, Chromatin immunoprecipitation; DBD, DNA binding domain; DMSO, Dimethyl sulfoxide; D
Regular articleOestrogen induced downregulation of TFPI expression is mediated by ERα
Keywords: ERα/β; Oestrogen rceptor alpha/beta; TFPI; Tissue factor pathway inhibitor; TF; tissue factor; E2; 17-β-oestradiol; EE2; 17-β-ethinyloestradiol; FUL; fulvestrant; CHX; cycloheximide; ERE; oestrogen response element; HRT; hormone replacement therapy; P
Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell–matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis
Keywords: G protein coupled estrogen receptor 30; Calpain; Fulvestrant; Cell adhesion; Breast cancer
Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression
Keywords: Non-small cell lung cancer; Epidermal growth factor receptor; Gefitinib; Resistance; Fulvestrant
The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer
Keywords: Aromatase inhibitor; Endocrine treatment; Fulvestrant; Hormone receptor-positive breast cancer; Selective estrogen receptor down-regulators; Selective estrogen receptor modulators;
Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy
Keywords: Breast cancer; Fulvestrant; Paclitaxel; Estrogen receptor; Drug resistance;
Respuesta hormonal de las células madre de mama y resistencia a tamoxifeno
Keywords: Estrógeno; Tamoxifeno; Fulvestrant; Células madre; Células madre cancerosas; Resistencia a terapia; Sox2; BiomarcadorEstrogen; Tamoxifen; Fulvestrant; Stem cells; Cancer stem cells; Resistance; Sox2; Biomarker
Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs
Keywords: Fulvestrant; MDM2; Chemotherapy; Estrogen receptor; Breast cancer;
Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant
Keywords: 4OHT; 4-hydroxytamoxifen; ATP; adenosine triphosphate; BSA; bovine serum albumin; CCD; charge coupled device; CDTA; 1,2-diaminocyclohexanetetraacetic acid monohydrate; DCC-FCS; dextran-coated charcoal-treated fetal calf serum; DMEM; Dulbecco's modified
ReviewExtending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor-Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action
Keywords: Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen;
A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor
Keywords: Anti-breast cancer agent; Oestrogen receptor; Acetyltanshinone IIA; Tamoxifen; Fulvestrant;
Assessment of the proliferative capacity of the flavanones 8-prenylnaringenin, 6-(1.1-dimethylallyl)naringenin and naringenin in MCF-7 cells and the rat mammary gland
Keywords: 8-PN; 8-Prenylnaringenin; 6-DMAN; 6-(1.1-dimethylallyl)naringenin; Nar; naringenin; E2; 17β-Estradiol; ER; estrogen receptor; TEB; terminal end bud; HRT; hormone replacement therapy; IGF-1; insulin-like growth factor; FGF; fibroblast derived growth facto
T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant
Keywords: Antiestrogen resistance; Breast cancer; Fulvestrant; HER2; c-Src
Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides
Keywords: Soluble epoxide hydrolase; Epoxy-eicosatrienoic acids; Fulvestrant; Competitive inhibition; X-ray structure;
Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie
Keywords: Endometrial cancer; Fulvestrant; Phase II study;
Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells
Keywords: Fulvestrant; Breast conservation therapy; Radiation; Hormonal therapy; Sequencing;
Effects of estradiol on the endocytic transport of vitamin D carrier protein in hepatocytes
Keywords: Estradiol; Endocytosis; Nutrient-carrier proteins; Hepatocytes; Vitamin D-binding protein; Fulvestrant;
Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: Case report and review of the literature
Keywords: Endometrial stromal sarcoma; Oestrogen receptor; Endocrine therapy; Fulvestrant; FES PET;
Bisphenol A interferes with thyroid specific gene expression
Keywords: TH; thyroid hormone; TR; TH receptor; TTFs; thyroid transcription factors; T4; tetra-iodothyronine; E2; 17-β estradiol; ICI; fulvestrant; Bisphenol A; Thyroid; Cell line; Zebrafish; Thyroid specific gene transcription;
Keywords: fulvestrant; metastatic breast cancer; network meta-analysis; progression-free survival